Chugai: Polivy approved for treatment of relapsed or refractory diffuse large B-cell lymphoma in Japan

Investor Update Chugai: Polivy approved for treatment of relapsed or refractory diffuse large B-cell lymphoma in Japan

Dear Investor,

Please find attached a press release by Chugai:
https://www.roche.com/dam/jcr:886cf513-18db-4809-a7d5-de8b66ca4b0e/en/210324_IR_Chugai_ePolivy_Approval.pdf

Do not hesitate to contact us for any further questions.

With best regards,

Roche Investor Relations
Dr. Karl Mahler Phone: [phone] e-mail: [e-mail]	Jon Kaspar Bayard Phone: [phone] e-mail: [e-mail]
Dr. Sabine Borngräber Phone: [phone] e-mail: [e-mail]	Dr. Bruno Eschli Phone: [phone] e-mail: [e-mail]
Dr. Birgit Masjost Phone: [phone] e-mail: [e-mail]	Dr. Gerard Tobin Phone: [phone] e-mail: [e-mail]
Investor Relations North America
Loren Kalm Phone: [phone] e-mail: [e-mail]	Dr. Lisa Tuomi Phone: [phone] e-mail: [e-mail]